Recent medical studies reveal that one in every seven thousand childbirths is affected by lysosomal storage diseases, a statistic that is rising, particularly in underdeveloped countries with limited awareness and medical resources. This growing prevalence is significantly contributing to the expansion of the global enzyme replacement therapy market, which is expected to be valued at an impressive USD 10,707.6 million by 2024.
Enzyme replacement therapy is crucial for treating rare diseases such as Gaucher disease and Fabry disease. Advances in medical technology and the increasing availability of sophisticated healthcare facilities, both public and private, are further propelling the market’s growth. The enzyme replacement therapy market is anticipated to expand at a healthy Compound Annual Growth Rate (CAGR) of 6.60% from 2024 to 2034.
Government initiatives to increase public awareness and lenient reimbursement policies are also driving market growth. By the end of the forecast period, the market is projected to reach a valuation of USD 20,289.1 million.
Enzyme Replacement Therapy Industry: Regional Insights
With nearly 25%-30% market share, North America dominated the Global Enzyme Replacement Therapy Industry in 2017, partly due to the presence of leading market players in the region. In developing regions such as Latin America, advancements in medical facilities are helping the region cope with the healthcare crisis. Medical facilities in Brazil are equivalent to hospitals in the United States, with some even exceeding American standards. Brazil offers everything from large, full-service hospitals to smaller, intimate private clinics.
Brazil has developed into a center of excellence for healthcare in Latin America, with major universities that support the research, teaching, and training of medical professionals. Western Europe is the second largest market globally and is expected to be valued at US$ 2,893.2 Mn by 2028, with France, Italy, and Spain projected to witness significant growth rates. Japan is expected to be the third largest market for enzyme replacement therapy.
Enzyme Replacement Therapy Market: Segmentation & Forecast
The Global Enzyme Replacement Therapy Industry has been segmented based on therapeutic condition, route of administration, distribution channel, and region. Therapeutic conditions in the enzyme replacement therapy markets include Fabry disease, Gaucher disease, mucopolysaccharidosis, Pompe disease, lysosomal acid lipase deficiency, and others.
Globally, the mucopolysaccharidosis therapeutic condition is the most attractive segment. The injectable segment remains the most lucrative route of administration in the Global Enzyme Replacement Therapy Industry. Among all distribution channels for enzyme replacement therapy, specialty treatment pharmacies are expected to be the most lucrative, followed by hospital pharmacies.
Key Research Findings
Enzyme replacement therapy is used in the treatment of rare diseases and the global market is projected to create incremental opportunity of US$ 6,448.3 Mn between 2022 and 2028
When compared to other established markets such as North America, the enzyme replacement therapy markets in Japan and Western Europe are expected to witness fast and steady growth, partly due to the increasing governmental support and growing demand for enzyme replacement therapy for the treatment of rare diseases.
Enzyme Replacement Therapy Market: Competitive Landscape
- Sanofi S.A. (Genzyme Corporation)
- Shire plc.
- Pfizer Inc.
- Alexion Pharmaceuticals Inc.
- BioMarin Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc.
- Johnson & Johnson Services Inc.
- Allergan plc.
- Leadiant Biosciences Inc.
Pompe Disease Treatment Market Is a type of treatment for certain genetic diseases that are caused by a deficiency in a specific enzyme. This therapy involves administering the missing enzyme to the patient, usually through intravenous infusion.
A Old Full Report Analysis Click Here
Key Segments of Enzyme Replacement Therapy Industry Survey
by Therapeutic Condition:
- Enzyme Replacement Therapy for Fabry Disease
- Enzyme Replacement Therapy for Gaucher Disease
- Enzyme Replacement Therapy for Mucopolysaccharidosis
- MPS I
- MPS II (Hunter Syndrome)
- MPS IVA (Morquio Syndrome, Type A)
- MPS VI (Maroteaux-Lamy Syndrome)
- MPS VII (Sly Syndrome)
- Enzyme Replacement Therapy for Pompe Disease
- Enzyme Replacement Therapy for Lysosomal Acid Lipase Deficiency
- Others
by Route of Administration:
- Oral Enzyme Replacement Therapy
- Injectable Enzyme Replacement Therapy
by Distribution Channel:
- Hospital Pharmacies
- Specialty Treatment Pharmacies
- Retail Pharmacies
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
